Sirtris Pharmaceuticals to Present at the Susquehanna International Group Emerging Trends Conference, November 1st, 2006
Posted on: Monday, 30 October 2006, 09:01 CST
Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that it will be presenting at the Susquehanna International Group Emerging Trends Conference in New York. Sirtris will discuss the Company's strategy for discovering and developing first in class therapeutics that modulate sirtuins, a recently discovered family of enzymes that promote healthy cellular function. The presentation will be delivered at 1:00 EST on Wednesday, November 1st, 2006.
About Sirtuins
Sirtuins are a recently discovered family of enzymes that promote normal cellular function. In particular, sirtuins improve the function of mitochondria which generate energy in cells. When organisms face adversity, sirtuins are activated as part of a natural process that maintains healthy function.
Therefore, sirtuins are attractive drug targets which may be therapeutically beneficial for diseases in which mitochondria are dysfunctional, often observed in diseases of aging. These diseases include metabolic diseases such as Type 2 Diabetes and other mitochondrial disorders. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and mitochondrial diseases.
Sirtris Pharmaceuticals was founded in 2004 by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal and has raised a total of $82 million since inception from investors including: Bessemer Venture Partners, Cardinal Partners, Cargill Ventures, Genzyme Ventures, Novartis Bioventures Fund, Polaris Venture Partners, QVT Fund LP, Skyline Ventures, The Wellcome Trust, Three Arch Partners, and TVM Capital. The company's headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.
Source: Business Wire
Related Articles
- Macerich and GI Partners Create a New Joint Venture
- Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
- Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
- Snelson Companies, Inc. Partners With GFI Energy Ventures, LLC
- Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
- Anthera Pharmaceuticals Secures $36M Venture Financing to Initiate Clinical Programs
- Pain Therapeutics and King Pharmaceuticals Initiate Clinical Program of a Second Abuse-Resistant Painkiller
- Pain Therapeutics and King Pharmaceuticals Receive Special Protocol Assessment for Remoxy(TM) and Commence Pivotal Phase III
- Prevalence of Cardiovascular Disease in the Seven Largest Pharmaceutical Markets With Forecasts 2004-2010
- CV Therapeutics and Solvay Pharmaceuticals Enter Into Co-Promotion Agreement for ACEON(R) (Perindopril Erbumine) Tablets
 |
 |
User Comments (0)
RSS Feeds